STOCK TITAN

Aprea Therapeutics, Inc. Stock Price, News & Analysis

APRE Nasdaq

Welcome to our dedicated page for Aprea Therapeutics news (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.

Aprea Therapeutics, Inc. (APRE) is a clinical-stage biopharmaceutical leader developing precision oncology therapies through synthetic lethality approaches. This page provides investors and researchers with timely updates on the company’s progress in targeting DNA damage response pathways in solid tumors.

Access authoritative reporting on Aprea’s pipeline developments, including its ATRN-119 and APR-1051 programs. Our curated news collection covers clinical trial milestones, regulatory updates, and strategic collaborations, helping stakeholders track innovations in targeted cancer therapies.

Key content includes updates on phase 1/2 trial results, FDA communications, intellectual property expansions, and research partnerships. All content is verified through primary sources to ensure accuracy in this fast-evolving therapeutic area.

Bookmark this page for centralized access to Aprea’s latest scientific advancements and corporate announcements. Check regularly for developments in next-generation oncology treatments leveraging synthetic lethality mechanisms.

Rhea-AI Summary

Aprea Therapeutics has announced the dosing of the first patient in the ACESOT-1051 Phase 1 trial for their oral WEE1 inhibitor, APR-1051. This study is evaluating APR-1051 as a monotherapy for patients with advanced solid tumors who have unmet medical needs. APR-1051, developed by Aprea, targets the WEE1 kinase, an enzyme involved in the DNA damage response pathway. The trial will assess safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy over 28-day cycles. The first part involves dose escalation, while the second part focuses on dose optimization. The trial aims to confirm APR-1051's safety and determine the recommended Phase 2 dose. Updates are expected by year-end 2024 with preliminary efficacy data in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
-
Rhea-AI Summary

Aprea Therapeutics announced that the Safety Review Committee (SRC) has approved dosing patients with ATRN-119 at 800 mg once daily in the ongoing ABOYA-119 clinical trial. ATRN-119, the first macrocyclic ATR inhibitor in clinic trials, has demonstrated a favorable safety profile through five dosage levels (up to 550 mg) with no dose-limiting toxicities. This advancement allows for Cohort 6 enrollment and positions Aprea to complete dose escalation and potentially release initial efficacy data by the second half of 2024. Clinical data show increasing systemic drug exposure with higher doses, and preliminary benefits observed in the trial include stable disease in two patients. The Phase 1 dose escalation is expected to conclude by the fourth quarter of 2024, with a recommended Phase 2 dosage to be identified by early 2025. Further Phase 2a cohort studies will begin in early 2025, aiming to evaluate ATRN-119's efficacy in advanced solid tumors with specific DDR pathway mutations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
-
Rhea-AI Summary

Aprea Therapeutics (NASDAQ: APRE) announced FDA clearance for their new oral WEE1 inhibitor, APR-1051, and plans to initiate Phase 1 clinical trials in June 2024. Their ATR inhibitor, ATRN-119, is progressing in the ABOYA-119 trial, with initial efficacy data expected in 2H 2024. The company presented four posters at the AACR Annual Meeting, including updates on these key programs. Aprea has $32.4 million in cash as of March 31, 2024, and recently raised up to $34 million through a private placement. First-quarter 2024 results showed an operating loss of $3.1 million, down from $4.6 million in the same period of 2023, and net loss narrowed to $2.8 million. R&D expenses increased to $1.6 million, while G&A expenses decreased to $1.9 million. They also appointed Nadeem Q. Mirza, M.D., as Chief Medical Officer, effective May 1, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
Rhea-AI Summary

Aprea Therapeutics (Nasdaq: APRE), a clinical stage biopharmaceutical company specializing in precision oncology, announced its participation in the 2024 RBC Capital Markets Global Healthcare Conference. The event is scheduled for May 14-15, 2024, in New York, NY. Management will be available for one-on-one meetings during the conference. Interested parties can arrange meetings through their conference representative.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
conferences
-
Rhea-AI Summary

Aprea Therapeutics, Inc. announces the appointment of Dr. Nadeem Q. Mirza as Chief Medical Officer, strengthening its leadership team. Dr. Mirza brings extensive experience in oncology and drug development, enhancing Aprea's clinical pipeline. The company also grants Dr. Mirza stock options and restricted stock units as inducement for his appointment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.05%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
none

FAQ

What is the current stock price of Aprea Therapeutics (APRE)?

The current stock price of Aprea Therapeutics (APRE) is $1.88 as of July 9, 2025.

What is the market cap of Aprea Therapeutics (APRE)?

The market cap of Aprea Therapeutics (APRE) is approximately 9.1M.
Aprea Therapeutics, Inc.

Nasdaq:APRE

APRE Rankings

APRE Stock Data

9.13M
4.49M
11.74%
42.03%
0.8%
Biotechnology
Pharmaceutical Preparations
Link
United States
DOYLESTOWN